Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease
American Journal of Health-System Pharmacy · 2025
DOI: 10.1093/ajhp/zxaf045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Thelma Barber und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Kidney Foundation Voices for Kidney Health. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Cardiovascular Diseases, Practice Guidelines as Topic, Pharmacists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben.
Abstract (Originalsprache)
Purpose
An estimated 37 million people currently live with chronic kidney disease in the US, which places them at increased risk for kidney disease progression, cardiovascular disease, and mortality. This review discusses current standard-of-care management of patients with chronic kidney disease, identifies key gaps in care, and briefly highlights how pharmacists can address gaps in care as members of the multidisciplinary care team. Summary Recent advances in guideline-directed medical therapies for patients with chronic kidney disease, including agents from the sodium-glucose cotransporter, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes, can dramatically improve cardiovascular-kidney-metabolic care and outcomes. Unfortunately, gaps in screening, diagnosis, and implementation of recommended therapies persist. Team-based models of care—inclusive of the person with chronic kidney disease—have the potential to significantly improve care and outcomes for people with chronic kidney disease by addressing current gaps in care.
Conclusion
As members of the multidisciplinary care team, pharmacists can play a critical role in addressing current gaps in care, including optimized use of guideline-directed medical therapies, in patients with chronic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Kidney Foundation Voices for Kidney Health.
- Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA.
- Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA.
- Division of Applied Clinical Sciences, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.
- Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA.
Zitieren
APA
Barber, T., Neumiller, J. J., Fravel, M. A., Page, R. L., & Tuttle, K. R. (2025). Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf045
Vancouver
Barber T, Neumiller JJ, Fravel MA, Page RL, Tuttle KR. Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf045
BibTeX
@article{Barber2025,
author = {Barber, Thelma and Neumiller, Joshua J and Fravel, Michelle A and Page, Robert L and Tuttle, Katherine R},
title = {Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
doi = {10.1093/ajhp/zxaf045}
}
EUVIMED